At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,183 enrolled
Drug / intervention
semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating semaglutide and placebo for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 3,183 participants across 228 sites in 21 countries.
Detailed Summary
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAlgeria, Argentina, Brazil, Canada, Denmark, Germany, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Romania, South Africa, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartJan 2017
Primary CompletionSep 2018
TodayJul 2026
First PostedFeb 26, 2016
Enrollment StartJan 17, 2017
Primary CompletionSep 25, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.3 years ago
Interventions
semaglutidedrug
For oral use once daily.
placebodrug
For oral use once daily.